Get the Stockscreener App
6.88
3.93%
0.26
After Hours:
6.88
Solid Biosciences Inc stock is traded at $6.88, with a volume of 790.77K.
It is up +3.93% in the last 24 hours and down -13.13% over the past month.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
See More
Previous Close:
$6.62
Open:
$6.76
24h Volume:
790.77K
Relative Volume:
0.63
Market Cap:
$677.33M
Revenue:
$14.79M
Net Income/Loss:
$-174.33M
P/E Ratio:
-3.4027
EPS:
-2.0219
Net Cash Flow:
$-157.44M
1W Performance:
+13.16%
1M Performance:
-13.13%
6M Performance:
+28.36%
1Y Performance:
+144.84%
1-Day Range:
$6.70
$6.93
1-Week Range:
$6.098
$6.93
52-Week Range:
$2.83
$8.8661
Solid Biosciences Inc Stock (SLDB) Company Profile
Name
Solid Biosciences Inc
Sector
Industry
Phone
617-337-4680
Address
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
6.88 | 651.74M | 14.79M | -174.33M | -157.44M | -2.0219 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-26 | Initiated | Guggenheim | Buy |
| Dec-04-25 | Initiated | Needham | Buy |
| Jun-26-25 | Initiated | Citigroup | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-13-24 | Initiated | Wedbush | Outperform |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-15-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | William Blair | Outperform |
| Mar-15-24 | Initiated | Citigroup | Buy |
| Mar-14-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | Piper Sandler | Neutral |
| May-27-21 | Initiated | Jefferies | Buy |
| Mar-16-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jul-28-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-07-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-19 | Initiated | Evercore ISI | Outperform |
| Aug-29-19 | Downgrade | Citigroup | Neutral → Sell |
| Aug-19-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-16-19 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| May-14-19 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-14-19 | Downgrade | Goldman | Neutral → Sell |
| Feb-08-19 | Upgrade | Citigroup | Sell → Neutral |
| Feb-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-18 | Initiated | Citigroup | Sell |
| Sep-06-18 | Initiated | Credit Suisse | Neutral |
View All
Solid Biosciences Inc Stock (SLDB) Latest News
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
J.P. Morgan Maintains Solid Biosciences(SLDB.US) With Buy Rating, Cuts Target Price to $11 - Moomoo
SLDB Stock Price, Quote & Chart | SOLID BIOSCIENCES INC (NASDAQ:SLDB) - ChartMill
Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months? - Insider Monkey
10 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Value Gem With Solid Fundamentals - ChartMill
SLDB Reiterated by Wedbush -- Price Target Maintained at $16.00 - GuruFocus
Solid Biosciences Price Target Maintained With a $16.00/Share by Wedbush - Moomoo
SLDB: Citigroup Lowers Price Target but Maintains Buy Rating | S - GuruFocus
H.C. Wainwright Remains a Buy on Solid Biosciences (SLDB) - The Globe and Mail
Citigroup Maintains Solid Biosciences (SLDB) Buy Recommendation - MSN
Solid Biosciences stock (US8317541063): Piper Sandler raises price target to $18 - AD HOC NEWS
Solid Biosciences Inc. to host webinar on SGT-003 gene therapy for Duchenne - Traders Union
Number of shareholders of Solid Biosciences Inc. – NASDAQ:SLDB - TradingView
Wedbush Adjusts Price Target on Solid Biosciences to $16 From $17, Maintains Outperform Rating - Moomoo
SLDB Maintained by Piper Sandler -- Price Target Raised to $18 - GuruFocus
Wedbush Maintains Solid Biosciences(SLDB.US) With Buy Rating, Cuts Target Price to $16 - Moomoo
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Solid Biosciences (SLDB) boosts cash to $380.7M while Q1 net loss widens - Stock Titan
Solid Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MSN Money - MSN
TradingKey - TradingKey
Solid Biosciences Inc expected to post a loss of 43 cents a shareEarnings Preview - TradingView
SLDB SEC FilingsSolid Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan
William Blair Maintains Solid Biosciences(SLDB.US) With Buy Rating - Moomoo
Solid Biosciences begins phase 3 trial for Duchenne therapy By Investing.com - Investing.com South Africa
Solid Biosciences begins phase 3 trial for Duchenne therapy - Investing.com
A Duchenne treatment reaches Phase 3 after 46 patients dosed - Stock Titan
Solid Biosciences Doses First Participant in Phase 3 IMPACT - GlobeNewswire
Solid Biosciences Chief Medical Officer presents targeted therapy delivery approach at Boston biotech conference - Traders Union
SLDB: JP Morgan Raises Price Target to $12 with Overweight Ratin - GuruFocus
Invus and affiliates hold 9.99% of Solid Biosciences (NASDAQ: SLDB) via warrants and shares - Stock Titan
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
One new Solid Biosciences employee gets 8,070 stock units - Stock Titan
SLDB: HC Wainwright & Co. Reiterates Buy Rating with $20 Target - GuruFocus
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy - marketscreener.com
Solid Biosciences to Showcase a Large Presence at the 29th - GlobeNewswire
Solid Bio wins new buy at Guggenheim on lead asset - MSN
Solid Biosciences receives EU orphan drug status for SGT-003 - Investing.com UK
Solid Biosciences (SLDB) Receives Orphan Drug Designation for SG - GuruFocus
Solid Biosciences receives EU orphan drug status for SGT-003 By Investing.com - Investing.com South Africa
Solid Biosciences Inc Stock (SLDB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):